Clinical trial Recruiting at 1 site Interventional Ages 20 to 70 Women only

Intelligent Sexual Health Help System for Gynecologic Cancer Patients

Official title: Intelligent Sexual Health LillyBot Information Support System for Gynecological Cancer Patients: Development, Test and Evaluation of Longitudinal Effects

Run by Chang Gung Memorial Hospital · NCT07794098 · Data updated 2026-11-12

A smartphone-based sexual health education and consultation system called LillyBot will be tested with gynecologic cancer patients to see if it improves sexual well-being.

Quick facts

Study typeInterventional
Ages20 Years to 70 Years
SexWomen only
Enrollment90 (estimated)
SponsorChang Gung Memorial Hospital
Academic / other
Locations1 site (Taoyuan, Guishan)
StatusRecruiting
StartedJune 17, 2026
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedSeptember 11, 2026
Trial IDNCT07794098 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 20-70 with gynecologic cancer diagnosed within the last six months, undergoing treatment, with a regular partner, and able to use a internet-enabled device, who can read/write Mandarin or Taiwanese.

Probably not a fit

Patients without access to internet-enabled devices or who do not engage with digital consultations may see limited or no benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial develops and tests LillyBot, an AI-powered chatbot and mobile health tool designed to provide real-time, personalized sexual health information and consultations for gynecologic cancer patients in Taiwan. The project follows a 3-year plan: building a needs assessment and the mHealth-enabled PROM module, designing and developing LillyBot, and then testing it in a prospective pretest-posttest randomized design with three groups. About 90 participants from a northern Taiwan medical center will be recruited and assigned to LillyBot-based consultations, online consultations with sexual health professionals, or online consultations with non-specialists, with data collected at baseline, 1 month, and 3 months to measure outcomes such as sexual distress, knowledge, attitudes, self-efficacy, behaviors, and satisfaction.

Why it matters

Potential benefit: If successful, LillyBot could provide accessible, personalized sexual health support and education for gynecologic cancer patients, potentially improving distress, knowledge, and satisfaction.

How similar studies have gone: Prior research in digital health for cancer-related sexual health shows promise, but this specific AI chatbot, LillyBot, and randomized design for GC patients is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women diagnosed with gynecologic cancer within 6 months prior to enrollment.
* Women receiving cancer treatment at the recruiting hospital.
* Aged 20 to 70 years, inclusive.
* Have a regular partner.
* Possesses and is able to use an internet-enabled mobile device (such as a smartphone or iPad).
* Able to clearly communicate and read/write in Mandarin or Taiwanese.

Exclusion Criteria:

* History of other malignant tumors.
* Intellectual disability or mental disorders.

Where it's running

  • Cheng Gung Memorial Hospital
    Taoyuan, Guishan, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.